London, United Kingdom
Tenpoint Therapeutics Ltd, founded in 2020 and headquartered in the United Kingdom, operates within the Biotechnology industry. The company is pioneering in the creation of engineered cell-based therapeutics aimed at restoring vision, aligning with its slogan, "Tenpoint is a global commercial-ready biotech developing groundbreaking treatments to rejuvenate vision in the aging eye."
By focusing on rejuvenating visual capacities in patients with ocular diseases, Tenpoint Therapeutics is positioned to make significant global impacts. Their ambitious approach to reimagining treatment for ocular conditions could redefine standards in this niche biotechnological field.
In July 2023, Tenpoint Therapeutics secured a $70.00M Series A investment from a consortium of reputable investors including Eight Roads Ventures, F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Albion VC, British Patient Capital, and UCL Tech Fund. This significant funding reflects trust in the company's vision and potential to impact the biotechnology landscape.
